AG
ACRS icon

Advisor Group’s Aclaris Therapeutics ACRS Stock Holding History

Advisor Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$2K Hold
1,000
– – ﹤0.01% 4945
2019
Q3 		$1K Buy
+1,000
New +$1.42K ﹤0.01% 5066
2017
Q4 		– Sell
-174
Closed -$4K – 4936
2017
Q3 		$4K Buy
174
+61
+54% +$1.64K ﹤0.01% 4331
2017
Q2 		$3K Buy
+113
New +$3.07K ﹤0.01% 4393

Other funds holding ACRS

MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group's ACRS Position: Q4 2019 in Review

Advisor Group held its Aclaris Therapeutics (ACRS) position steady in Q4 2019 at 1,000 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #4945.

Advisor Group first reported a position in ACRS in Q2 2017 and has held it in 4 quarters since. The position peaked at $4K in Q3 2017. 79 funds tracked by Wall St. Rank hold ACRS as of Q4 2019.

  • Advisor Group held 1,000 shares of Aclaris Therapeutics worth $2K as of Q4 2019.
  • Advisor Group left its Aclaris Therapeutics share count unchanged in Q4 2019.
  • Aclaris Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4945 holding.
  • Advisor Group first reported a position in Aclaris Therapeutics in Q2 2017 and has held it in 4 quarters since.
  • Advisor Group's Aclaris Therapeutics position peaked at $4K in Q3 2017.
  • 79 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.